Abstract Epithelial-mesenchymal transitions (EMTs), the acquisition of mesenchymal
features from epithelial cells, occur during some biological processes and are classified into …

The fact that various immune cells, including macrophages, can be found in tumor tissues
has long been known. With the introduction of concept that macrophages differentiate into a …

Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of
inflammatory and immune cells. Tumor‐associated chronic inflammation is a hallmark of …

Improved understanding of the immune system and its role in cancer development and
progression has led to impressive advances in the field of cancer immunotherapy over the …

Simple Summary Hepatocellular carcinoma (HCC) constitutes a major health burden,
accounting for> 80% of primary liver cancers globally. Inflammation has come into the …

Simple Summary Since the targeting of a single pro-angiogenic factor fails to improve
oncological disease outcome, significant efforts have been made to identify new pro …

Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma
(HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70 …

It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …

It is well known that the microenvironment of solid tumors is rich in inflammatory cells that
influence tumor growth and development. Macrophages, called tumor-associated …